When the U.S. Supreme Court lifted the Fifth Circuit’s stay of the FDA’s 2023 mifepristone telehealth rules Thursday evening, the order arrived without a word of explanation. No reasoning, no analysis — just a quiet grant, as if the forces arrayed on the other side of this case were too formidable to confront directly.

Against that backdrop, the willingness of Justices Clarence Thomas and Samuel Alito — and, from the Fifth Circuit bench, Judge Stuart Kyle Duncan — to say plainly what this case is actually about deserves to be recognized for what it is: genuine judicial courage in the face of one of the most powerful and well-resourced interest coalitions in American public life.

Make no mistake about what that coalition looks like. On one side of this litigation stand drug manufacturers Danco Laboratories and GenBioPro, companies that have built a lucrative mail-order abortion pipeline flowing into states that have democratically chosen to protect unborn life and who came to the Supreme Court claiming injury because a court order threatened to slow the profits.

Behind them stand federal bureaucrats who used their regulatory authority not to protect women but to advance an explicitly political agenda, rewriting mifepristone’s safety rules in the wake of Dobbs, not because the science demanded it but because the Biden White House demanded it.

And shielding all of them stand blue-state attorneys general and legislatures that enacted shield laws specifically designed to prevent states like Louisiana from holding anyone legally accountable for any of it. This is Abortion’s Goliath — lavishly funded, institutionally entrenched, and accustomed to winning.

The Supreme Court's order does not end the fight, however; the case now returns to the Fifth Circuit, where a merits panel will have the opportunity to fully confront the FDA’s regulatory failures on the substance.

Thomas makes his case with characteristic precision. The Comstock Act is a federal statute still on the books, which makes it a crime to ship abortifacients through the mail or common carriers. Danco and GenBioPro ship mifepristone to pharmacies, which ship it onward to end users. The result, in Louisiana alone, is nearly 1,000 illegal abortions every month.

Thomas names this without flinching: The manufacturers are running a “criminal enterprise,” and a company cannot come to a court of equity seeking emergency relief from an order that merely makes it harder to break the law. The simplicity of the argument is its strength. Strip away the regulatory complexity, the APA briefing, the standing doctrine and what you have is a business model built on conduct that federal law prohibits. Thomas refuses to let the legal scaffolding obscure that fact.

Alito is equally unflinching, and more expansive. He precisely traces how the 2023 REMS — the FDA rule eliminating the requirement that women see a physician before receiving mifepristone — was born not of science but of political will. The Biden administration pledged to use "every lever" to expand medication abortion access after Dobbs v. Jackson Women’s Health Organization, an opinion authored by Alito himself.

The FDA was that lever. The 2023 rule change was that pull. And crucially, the FDA’s own current leadership has since conceded that the prior REMS approvals suffered from a “lack of adequate consideration” of patient safety. The agency confessed to the corner-cutting. Yet the rules remain in force, and the manufacturers who devoted barely three pages of their 80-plus-page applications to the question of irreparable harm were rewarded with emergency relief from the highest court in the land.

Duncan, from his Fifth Circuit perch, provided the analytical architecture that gives these dissents their firmest footing. His opinion documents the FDA’s circular logic with surgical care: The agency eliminated adverse-event reporting requirements for mifepristone, then cited the resulting absence of adverse-event data as proof the drug was safe to dispense remotely.

Duncan documents the agency’s reliance on literature it simultaneously admitted did not support its own conclusions. He notes that the FDA, faced with Louisiana’s challenge, declined to defend the 2023 REMS on the merits at all. Behind every one of these regulatory failures, Duncan reminds us, are real women receiving powerful drugs through the mail, without a physician present, exposed to complication rates the FDA’s own label frankly acknowledges. And unborn children whose humanity Louisiana has declared in its own statutes, and whose lives that state sought to protect.

Thomas, Alito and Duncan are not naive about the world they inhabit. They know the pressures that bear on institutions when powerful industries, activist bureaucracies, and coordinated legal campaigns converge on a question. They wrote anyway. They named what they saw anyway.

In a legal landscape where the easiest path is always a wordless order and a quiet retreat, that willingness to stand and be counted for vulnerable women, for unborn children, for states trying to govern themselves is worth honoring.